Fut, nem toboroz1/2. fázis
A phase 1/phase 2 study to investigate safety, tolerability and efficacy with TG01/QS-21 vaccine administration in patients with confirmed KRAS or NRAS codon 12/13 mutation and high-risk smoldering multiple myeloma or multiple myeloma and evidence of measurable disease ≥ 1 line of treatment.
Key facts
- Where
- Oslo, NorvégiaSee the site
- Phase
- 1/2. fázis
Where in Norvégia
- Oslo University Hospital HFOslo, NorvégiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oslo University Hospital Hf
- Trial code
- EU 2022-502275-39-00
- Record updated
- 2026. június 11.